A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis
Latest Information Update: 13 Dec 2021
At a glance
- Drugs Ozanimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 15 Oct 2021 Results of Post hoc analysis, assessing the mechanism of action of ozanimod and investigating whether leukocytes remaining after treatment shift towards an immunosuppressive or proinflammatory state, presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 09 Sep 2019 According to an Celgene Corporation media release, data from this study will be presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
- 26 Mar 2018 Status changed from active, no longer recruiting to completed.